Guggenheim assumed coverage on shares of Icosavax (NASDAQ:ICVX – Get Free Report) in a research note issued to investors on Friday, Briefing.com reports. The firm set a “buy” rating and a $28.00 price target on the stock. Guggenheim’s price target indicates a potential upside of 200.75% from the company’s current price.
ICVX has been the topic of several other reports. Oppenheimer reiterated an “outperform” rating and set a $25.00 target price on shares of Icosavax in a report on Monday, October 2nd. William Blair reiterated an “outperform” rating on shares of Icosavax in a research note on Wednesday.
Icosavax Stock Up 0.1 %
Icosavax (NASDAQ:ICVX – Get Free Report) last announced its quarterly earnings results on Monday, August 14th. The company reported ($0.59) EPS for the quarter, beating the consensus estimate of ($0.60) by $0.01. On average, sell-side analysts anticipate that Icosavax will post -2.36 EPS for the current fiscal year.
Institutional Investors Weigh In On Icosavax
Hedge funds have recently made changes to their positions in the stock. GSA Capital Partners LLP bought a new position in Icosavax in the third quarter worth about $199,000. Northern Trust Corp raised its stake in shares of Icosavax by 11.8% during the 3rd quarter. Northern Trust Corp now owns 271,609 shares of the company’s stock worth $2,105,000 after acquiring an additional 28,686 shares in the last quarter. Federated Hermes Inc. bought a new position in shares of Icosavax during the 3rd quarter worth approximately $29,000. UBS Group AG boosted its stake in Icosavax by 97.6% in the third quarter. UBS Group AG now owns 14,544 shares of the company’s stock valued at $113,000 after acquiring an additional 7,183 shares in the last quarter. Finally, Barclays PLC boosted its stake in Icosavax by 3,589.5% in the third quarter. Barclays PLC now owns 202,182 shares of the company’s stock valued at $1,567,000 after acquiring an additional 196,702 shares in the last quarter. 92.59% of the stock is currently owned by hedge funds and other institutional investors.
Icosavax, Inc, a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target.
- Five stocks we like better than Icosavax
- How to Invest in Canada for Beginners
- Williams-Sonoma is a steal for buy-and-hold investors
- What is the NASDAQ Stock Exchange?
- A closer look at Warren Buffett’s latest surprise purchase
- Stock Market Upgrades: What Are They?
- GE stock surges to six-year high: What’s behind the move?
Receive News & Ratings for Icosavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icosavax and related companies with MarketBeat.com's FREE daily email newsletter.